# US 2006/0078556 A1 · Antibodies and epitopes specific to tRNA synthetase fragments

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0078556 A1
- Document ID: US20060078556A1
- Status: Published application
- Kind: A1
- Application number: 10/962,062
- Filed: 2004-10-07
- Published: 2006-04-13
- Earliest claimed: 2004-10-07
- Inventors: Paul Glidden
- Web page: https://patentgrep.com/patent/US20060078556A1

## CPC

- C07K 16/40: against enzymes
- A61K 2039/505: {comprising antibodies}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to antibodies that specifically bind to an epitome of a tRNA synthetase fragment. Such epitopes are preferably N-terminus epitopes or bind to the N-terminus of a tRNA synthetase fragment. The invention also relates to epitope peptides useful in generating the above antibodies.

## Claims

### Claim 1

An antibody that specifically binds to a tRNA synthetase fragment.

### Claim 2 (depends on 1)

The antibody of claim 1 wherein said tRNA synthetase fragment is a tryptophanyl tRNA synthetase fragment.

### Claim 3 (depends on 1)

The antibody of claim 1 wherein said tRNA synthetase fragment is a human tRNA synthetase fragment.

### Claim 4 (depends on 1)

The antibody of claim 1 wherein said tRNA synthetase fragment is angiostatic.

### Claim 5 (depends on 1)

The antibody of claim 1 wherein said tRNA synthetase fragment is selected from the group consisting of SEQ ID NOS: 12-17, 24-29, 36-41, 48-53, and any homologs and analogs thereof.

### Claim 6 (depends on 1)

The antibody of claim 1 wherein said antibody binds to an epitope of about 5 to about 30 amino acids of said tRNA synthetase fragment.

### Claim 7 (depends on 6)

The antibody of claim 6 wherein said epitope is an N-terminus epitope.

### Claim 8 (depends on 7)

The antibody of claim 7 wherein said epitope includes the N-terminus of said tRNA synthetase fragment.

### Claim 9 (depends on 1)

The antibody of claim 1 wherein said antibody is selected from the group consisting of a polyclonal antibody, a monoclonal antibody, a chimeric antibody, an anti-idiotypic antibody, and an antibody fragment.

### Claim 10

An epitope-bearing polypeptide comprising of a peptide sequence of at least about 5 amino acids of a tRNA synthetase fragment, or a homolg or analog thereof.

### Claim 11 (depends on 10)

The epitope-bearing polypeptide of claim 10 wherein said tRNA synthetase fragment is a human tRNA synthetase fragment.

### Claim 12 (depends on 10)

The epitope-bearing polypeptide of claim 10 wherein said tRNA synthetase fragment is a tryptophanyl tRNA synthetase fragment.

### Claim 13 (depends on 10)

The epitope-bearing polypeptide of claim 10 wherein said tRNA synthetase fragment is angiostatic.

### Claim 14 (depends on 10)

The epitope-bearing polypeptide of claim 10 wherein said tRNA synthetase fragment is selected from the group consisting of: SEQ ID NOS: 12-17, 24-29, 36-42, and 48-53.

### Claim 15 (depends on 10)

The epitope-bearing polypeptide of claim 10 wherein said epitope is an N-terminus epitope.

### Claim 16 (depends on 15)

The epitope-bearing polypeptide of claim 15 wherein said epitope is comprises the N-terminus of said tRNA synthetase.

### Claim 17 (depends on 10)

The epitope-bearing polypeptide of claim 10 wherein said peptide comprises of an amino acid sequence from amino acid residue of about 1 to about 5 of a polypeptide selected from the group consisting of SEQ ID NOS: 12-17, 24-29, 36-41, 48-53, and any homologs and analogs thereof.

### Claim 18 (depends on 10)

The epitope-bearing polypeptide of claim 10 wherein said peptide comprises of an amino acid sequence from amino acid residue of about 1 to about 15 of a polypeptide selected from the group consisting of SEQ ID NOS: 12-17, 24-29, 36-41, 48-53, and any homologs and analogs thereof.

### Claim 19 (depends on 10)

The epitope-bearing polypeptide of claim 10 wherein said peptide comprises of an amino acid sequence from amino acid residue of about 1 to about 25 of a polypeptide selected from the group consisting of SEQ ID NOS: 12-17, 24-29, 36-41, 48-53, and any homologs and analogs thereof.

### Claim 20 (depends on 10)

The epitope-bearing polypeptide of claim 10 wherein said peptide comprises of an amino acid sequence from amino acid residue of about 10 to about 15 of a polypeptide selected from the group consisting of SEQ ID NOS: 12-17, 24-29, 36-41, 48-53, and any homologs or analogs thereof.

### Claim 21 (depends on 10)

The epitope-bearing polypeptide of claim 10 wherein said peptide comprises of an amino acid sequence from amino acid residue of about 10 to about 25 of a polypeptide selected from the group consisting of SEQ ID NOS: 12-17, 24-29, 36-41, 48-53, and any homologs or analogs thereof.

### Claim 22 (depends on 10)

The epitope-bearing polypeptide of claim 10 wherein said peptide comprises of an amino acid sequence from amino acid residue of about 10 to about 35 of a polypeptide selected from the group consisting of SEQ ID NOS: 12-17, 24-29, 36-41, 48-53, and any homologs or analogs thereof.

### Claim 23 (depends on 10)

The epitope-bearing polypeptide of claim 10 wherein said peptide comprises of an amino acid sequence from amino acid residue of about 20 to about 25 of a polypeptide selected from the group consisting of SEQ ID NOS: 12-17, 24-29, 36-41,48-53, and any homologs and analogs thereof.

### Claim 24 (depends on 10)

The epitope-bearing polypeptide of claim 10 wherein said peptide comprises of an amino acid sequence from amino acid residue of about 20 to about 35 of a polypeptide selected from the group consisting of SEQ ID NOS: 12-17, 24-29,36-41, 48-53, and any homologs and analogs thereof.

### Claim 25 (depends on 10)

The epitope-bearing polypeptide of claim 10 wherein said peptide comprises of an amino acid sequence from amino acid residue of about 20 to about 45 of a polypeptide selected from the group consisting of SEQ ID NOS: 12-17, 24-29, 36-41, 48-53, and any homologs and analogs thereof.

### Claim 26 (depends on 10)

A polynucleotide sequence encoding the epitope-bearing polypeptide of claim 10.
